The mission of the Institut Jules Bordet's Department of Internal Medicine is to assume responsibilitiy regarding:
- Organising, with senior doctors from other specialities, the hospital's medical activity and support for undergraduate and postgraduate students
- Coordinating the various sister medical specialities of internal medicine, with the exception of those represented by departments concerned specifically with medical oncology and haematology.
- Intensive care
- The oncological emergencies room
- The infectious diseases clinic.
- Providing training in internal medicine for medical students and doctors training to be a specialist during the core years of internal medicine studies and higher training in internal medicine.
The Department of Internal Medicine offers expertise in the various fields of internal medicine while specialising in caring for patients suffering from oncological diseases:
- Oncological intensive care
- Oncological emergencies
- Infectious diseases
- Other medical specialities such as pnuemology
Every autumn the Department of Internal Medicine organizes an international meeting in French that is dedicated specifically to the severe complications that occur in patients suffering from a cancerous disease.
The department managers have developed two websites dedicated to cancer complications: www.oncorea.com for acute problems and www.pneumocancero.com for chronic problems (with particular focus on thoracic oncology).
The department has a continuous intake of medical students (Master's) and trainee specialists (internal medicine and sister disciplines) who follow training courses in internal medicine and in the department's more specific sectors. They are supported during seminars and specific tours.
In addition, the responsible doctors participate actively in the teaching of medical semiology, internal medicine clinical practice for the ULB's Master's in medicine, and the ULB's Master's specialising in internal medicine.
Research projects
Project 1 (in progress)
L’inflammation a-t-elle une implication significative dans l’évolution du cancer bronchique ?
- Project initiator: Dr Julie Gorham
- Financing: Intensive oncological care unit
Project 2
COHESIS : Collaboration and Outreach in Hematological patients with/without Sepsis
- Project initiator : Dr Anne-Pascale Meert
- Financing : Amis de l’Institut Bordet
- Collaboration : GrrrOH, NINE-I, HEMICU, DISPROPICUS, University of Ghent, University of Rotterdam
Project 3 (in progress)
RETRO-TARGETICU : Impact and outcome of patients admitted to ICU with cancer treated with targeted therapy
- Project initiator : Dr Anne-Pascale Meert
- Financing: awaiting
- Collaboration: Nine I
Project 4
IMMUNO-REA : Caractéristiques et prise en charge des patients atteints d’une tumeur solide traités par immunothérapie admis en réanimation
- Project initiator : Dr Anne-Pascale Meert
- Financing: Intensive oncological care unit
- Collaboration: GrrrOH
Project 5
YELENA : Characteristics and outcomes of cancer patients with acute respiratory distress syndrome potentially fulfilling inclusion criteria for veno-venous extracorporeal membrane oxygenation: a multicenter prospective descriptive analysis
- Project initiator : Dr Anne-Pascale Meert
- Financing: Intensive oncological care unit
- Collaboration: Dr. Schellongowski (University of Vienna) and Nine I
Project 6 (in progress)
Recommandations de pratique clinique pour le patient atteint d’une affection maligne admis en unité de soins intensifs.
- Project initiator : Dr Anne-Pascale Meert
- Financing: Intensive oncological care unit
Our team
Head of department
Prof. Anne-Pascale Meert
(Caroline Gustin : Secretary)
Intensive care and oncological emergencies
Prof. Jean-Paul Sculier
Prof. Thierry Berghmans, head of clinic
Dr Bogdan Grigoriu, deputy head of clinic
Dr Julie Gorham, resident
Infectious diseases clinic
Prof. Michael Aoun, head of clinic
Dr Aspasia Georgala
Dr Angela Loizidou
Medical speciality
Dr Bogdan Grigoriu, pulmonologist
Rhumatology
Dr Simenon
Scientific publications
SMAD4 Mutation in Small Cell Transformation of Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.
Authors : DHaene N, Le Mercier M, Salmon I, Mekinda Z, Remmelink M, Berghmans T
Year : 2019
Journal : Oncologist
Volume : 24
Pages : 9-13
Long-term health-related quality of life of critically ill patients with haematological malignancies: a prospective observational multicenter study.
Authors : Ehooman F, Biard L, Lemiale V, Contou D, de Prost N, Mokart D, Pène F, Kouatchet A, Mayaux J, Demoule A, Vincent F, Nyunga M, Bruneel F, Rabbat A, Lebert C, Perez P, Meert AP, Benoit D, Hamidfar R, Darmon M, Azoulay E, Zafrani L
Year : 2019
Journal : Ann Intensive Care
Volume : 9
Pages : 2
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Authors : Lemiale V, Meert AP, Vincent F, Darmon M, Bauer PR, Van de Louw A, Azoulay E
Year : 2019
Journal : Ann Intensive Care
Volume : 9
Pages : 25
The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses.
Authors : Rosière R, Berghmans T, de Vuyst P, Amighi K, Wauthoz N
Year : 2019
Journal : Cancers (Basel)
Volume : 11
[Lung cancer: Prognosis in intensive care depends mainly on the acute complication].
Authors : Gorham J, Ameye L, Paesmans M, Berghmans T, Sculier JP, Meert AP
Year : 2019
Journal : Rev Mal Respir
Volume : 36
Pages : 333-341